Glycostat® is an intravenous sensor specifically for tight glycemic control (TGC) in the critical care market.
The Glycostat® system is intended to continuously measure, record and track the blood glucose level (BGL) in critically ill patients (i.e., those patients under intensive-care treatment within an ICU) and to provide appropriate alarms in case of hypo- and hyperglycemic readings by the device.
In addition the Glycostat® system is intended to keep the blood Glucose level within set limits by giving advice on needed insulin infusion rate.
The GLUCOSTAT project has received funding from the European Union’s Horizon 2020 research and innovation
programme under grant agreement 777691
The Glycostat® system, has been granted the CE mark in may 2021
Glycostat has an advanced algorithm and an interface to an insulion infusion pump is foreseen.